2015
DOI: 10.1053/j.gastro.2015.04.014
|View full text |Cite
|
Sign up to set email alerts
|

Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients

Abstract: Bariatric surgery induced the disappearance of NASH from nearly 85% of patients and reduced the pathologic features of the disease after 1 year of follow-up. It could be a therapeutic option for appropriate morbidly obese patients with NASH who do not respond to lifestyle modifications. More studies are needed to determine the long-term effects of bariatric surgery in morbidly obese patients with NASH.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

20
393
2
23

Year Published

2015
2015
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 632 publications
(438 citation statements)
references
References 39 publications
20
393
2
23
Order By: Relevance
“…Multi-centre validation studies are needed before MR elastography can replace biopsy in NAFLD clinical trials. 176,177 .…”
Section: [H2] Epigeneticsmentioning
confidence: 99%
“…Multi-centre validation studies are needed before MR elastography can replace biopsy in NAFLD clinical trials. 176,177 .…”
Section: [H2] Epigeneticsmentioning
confidence: 99%
“…Exposure to these higher levels might play a part in the development of fatty liver disease and steatohepatitis [57] . It is reassuring that weight reduction clears hepatic fatty infiltration rapidly whether the weight reduction is due to surgical intervention or dietary restriction alone [22,58] .…”
Section: Bile Acids Steatohepatitis and Bilopancreatic Diversionmentioning
confidence: 99%
“…Since the data discussed above [10][11][12][13] indicates that, contrary to popular belief, there is an important risk of progression with NAFL to more serious fibrotic liver disease over time, we suggest it is now an appropriate time to consider changing the focus of the primary endpoint used in therapeutic trials for NAFLD, be it pharmacologic, life-style 14 or surgical 15 . The aim of the primary care physician and the metabolic clinician at least, needs to focus on prevention or reversal of early disease.…”
Section: A C C E P T E D Accepted Manuscriptmentioning
confidence: 86%